Vaccines

Delonix Bioworks' next-gen meningitis B vaccine, DX-104, is cleared for human trials in China and Australia, aiming to challenge the market leaders.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

As spring tick season begins, a devastating disease threatens cattle herds. Experts urge early vaccination to prevent massive economic and animal losses.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Landmark legislation targets pharmacy benefit managers to end restrictive practices, promising better access for patients with complex diseases.

A new partnership between Southern Research and Pathogenus Consulting combines US labs with a European network to fast-track treatments for global health threats.

After a four-year campaign, the World Health Organization is poised to recognize a silent liver epidemic, setting the stage for a new global NCD strategy.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Amid a relentless outbreak, Brazil launches a massive pilot program for the IXCHIQ® vaccine, a critical test for public health and global preparedness.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

Bolstered by a massive capital infusion and strong investor demand, Vaxcyte is set to accelerate its broad-spectrum vaccine pipeline against market leaders.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

Following the departure of its R&D head, Immunocore streamlines leadership, betting on internal experts to drive its next wave of innovative therapies.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.